Cargando…
Risk of consecutive immunogenic failure in switchers of anti-tumor necrosis factor alpha among patients with inflammatory bowel diseases
BACKGROUND: Evidence regarding the risk of immunogenicity in patients with inflammatory bowel disease (IBD) who switched anti-tumor necrosis factor alpha (anti-TNFα) therapies to a subsequent anti-TNFα (either infliximab or adalimumab) is conflicting. We aimed to assess the risk of consecutive immun...
Autores principales: | Yanai, Henit, Ungar, Bella, Kopylov, Uri, Fischler, Tali Sharar, Biron, Irit Avni, Ollech, Jacob E., Goren, Idan, Matar, Manar, Perets, Tsachi Tsadok, Shamir, Raanan, Dotan, Iris, Amir, Shira, Assa, Amit |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8785344/ https://www.ncbi.nlm.nih.gov/pubmed/35082920 http://dx.doi.org/10.1177/17562848211068659 |
Ejemplares similares
-
A Real-World Prospective Cohort Study of Patients With Newly Diagnosed Crohn’s Disease Treated by a Multidisciplinary Team: 1-Year Outcomes
por: Yanai, Henit, et al.
Publicado: (2023) -
Intestinal Fatty Acid Binding Protein Levels in Pediatric Celiac Patients in Transition From Active Disease to Clinical and Serological Remission
por: Hoofien, Assaf, et al.
Publicado: (2021) -
Serologic Response and Safety after a Third Dose of the COVID-19 BNT162b2 Vaccine in Patients with Inflammatory Bowel Diseases
por: Edelman-Klapper, Hadar, et al.
Publicado: (2023) -
Vedolizumab Is Associated with Longer Drug Sustainability Compared to Infliximab in Moderate-to-Severe Ulcerative Colitis: Long-Term Real-World Cohort Data
por: Konikoff, Tom, et al.
Publicado: (2023) -
Clinical approach to skin eruptions induced by anti-TNF agents among patients with inflammatory bowel diseases: insights from a multidisciplinary IBD-DERMA clinic
por: Yanai, Henit, et al.
Publicado: (2021)